IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFß cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC) Altorki, N. K., Reck, M., Wakelee, H., Felip, E., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Novello, S., McCune, S., Li, H., Molinero, L., Mueller, S., Bennett, E., Gitlitz, B. J., McNally, V. A., Ballinger, M., Nabet, B., Srivastava, M. K., Zhou, C. ELSEVIER. 2023: S732-S733

View details for DOI 10.1016/j.annonc.2023.09.742

View details for Web of Science ID 001087480201591